Financials in USD. Standardized financial statements.
A compact view of how Shanghai Junshi Biosciences Co., Ltd. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $2.43B | $1.95B | $1.50B | $1.45B | $4.02B | $1.59B | $775.09M | $934,000 | $1.15M | $3.76M |
| Revenue Growth? | +24.9% | +29.7% | +3.4% | -63.9% | +152.4% | +105.8% | +82886.0% | -18.6% | -69.4% | 0.0% |
| Cost of Revenue? | $664.69M | $498.86M | $667.29M | $526.28M | $1.26B | $372.53M | $90.68M | $267,000 | $446,000 | $986,000 |
| Gross Profit? | $1.76B | $1.45B | $835.26M | $927.21M | $2.77B | $1.22B | $684.40M | $667,000 | $702,000 | $2.77M |
| Gross Margin? | +72.3% | +74.4% | +55.6% | +63.8% | +68.7% | +76.6% | +88.3% | +71.4% | +61.1% | +73.8% |
| Operating Expenses? | $2.67B | $2.75B | $3.29B | $3.68B | $3.36B | $2.89B | $1.45B | $678.69M | $346.44M | $151.08M |
| Operating Income? | -$909.47M | -$1.30B | -$2.45B | -$2.75B | -$592.71M | -$1.67B | -$117.26M | -$104.66M | -$44.44M | -$24.53M |
| EBITDA? | -$599.43M | -$1.02B | -$2.16B | -$2.35B | -$308.26M | -$1.49B | -$690.23M | -$685.42M | -$302.43M | -$122.59M |
| Income Before Tax | -$995.34M | -$1.36B | -$2.49B | -$2.68B | -$592.65M | -$1.67B | -$763.12M | -$717.71M | -$320.74M | -$131.25M |
| Income Tax Expense | -$13.52M | $22.55M | $43.99M | -$93.11M | $135.53M | -$3.82M | -$18.89M | -$1.21M | $58,000 | $241,000 |
| Net Income? | -$851.83M | -$1.28B | -$2.28B | -$2.39B | -$718.56M | -$1.67B | -$743.92M | -$716.41M | -$320.84M | -$131.97M |
| EPS? | $-0.84 | $-1.30 | $-2.32 | $-2.60 | $-0.81 | $-2.02 | $-0.95 | $-1.19 | $-0.42 | $-0.17 |
| Diluted EPS? | $-0.84 | $-1.30 | $-2.32 | $-2.60 | $-0.81 | $-2.02 | $-0.95 | $-1.19 | $-0.42 | $-0.17 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality